ASH 2023 | 55-month follow-up from GLOW: fixed-duration Ibr+Ven vs Clb+O in treatment naïve CLL
Talha Munir, MD, Leeds Teaching Hospitals NHS Trust, Leeds, UK, presents the results of the 55-month follow-up from the Phase III GLOW trial (NCT03462719), comparing first-line fixed-duration ibrutinib plus venetoclax (Ibr+Ven) vs chlorambucil plus obinutuzumab (Clb+O) in patients with previously untreated chronic lymphocytic leukemia (CLL). The combination of Ibr+Ven resulted in superior progression-free survival (PFS). Dr Munir also discusses the findings of the subgroup analyses by IGHV and measurable residual disease (MRD). This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
